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Abstract
Background: Several models have been proposed to predict the short-term outcome of acute-on-chronic liver
failure (ACLF) after treatment. We aimed to determine whether better decisions for artificial liver support system
(ALSS) treatment could be made with a model than without, through decision curve analysis (DCA).
Methods: The medical profiles of a cohort of 232 patients with hepatitis B virus (HBV)-associated ACLF were
retrospectively analyzed to explore the role of plasma prothrombin activity (PTA), model for end-stage liver disease
(MELD) and logistic regression model (LRM) in identifying patients who could benefit from ALSS. The accuracy and
reliability of PTA, MELD and LRM were evaluated with previously reported cutoffs. DCA was performed to evaluate
the clinical role of these models in predicting the treatment outcome.
Results: With the cut-off value of 0.2, LRM had sensitivity of 92.6 %, specificity of 42.3 % and an area under the
receiving operating characteristic curve (AUC) of 0.68, which showed superior discrimination over PTA and MELD.
DCA revealed that the LRM-guided ALSS treatment was superior over other strategies including “treating all” and
MELD-guided therapy, for the midrange threshold probabilities of 16 to 64 %.
Conclusions: The use of LRM-guided ALSS treatment could increase both the accuracy and efficiency of this
procedure, allowing the avoidance of unnecessary ALSS.
Keywords: Model for end-stage liver disease, Logistic regression model, Acute-on-chronic liver failure, Hepatitis B
virus, Decision curve analysis
Background
Acute-on-chronic liver failure (ACLF) is characterized by se-
vere jaundice, coagulopathy, hepatic encephalopathy (HE),
and high morbidity and mortality. Hepatitis B virus (HBV)
infection is the commonest cause of ACLF in the Asian re-
gion [1]. Currently, the treatment of HBV-associated ACLF
(HBV-ACLF) is based on two main regimes – antiviral treat-
ment and artificial liver support system (ALSS) in China [2].
Antiviral therapy with nucleos(t)ide analogues has been
proven to significantly improve prognosis and survival rate
in HBV-ACLF patients [3]. However, the use of the ALSS
has shown a variable range of safety and efficiency in several
clinical trials [4–8]. In the last decade, several models have
been proposed to predict the short-term outcome of HBV-
ACLF after treatment. For instance, antiviral treatment can
significantly decrease the 3-month mortality only in patients
with the model for end-stage liver disease (MELD) score
below 30, compared with those with higher MELD scores
[9]. Another study suggested that ACLF patients with lower
MELD scores showed significantly improved prognosis
compared with those with higher MELD scores [10]. There-
fore, the variable results of the ALSS treatment in terms of
cost-effectiveness might be explained by the lack of guidance
of such predictive models. An ideal prediction model may
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provide objective information about whether future treat-
ment is likely to result in a favorable outcome or survival.
Recently, some studies revealed higher diagnostic accur-
acy for predictive models which combined liver dysfunc-
tion with etiological factor (e.g. HBV). In particular, Zheng
et al., in a population of 452 patients with diagnosis of
HBV-ACLF, established the logistic regression model
(LRM) score, with an area under the receiving operating
characteristic curve (AUC) of 0.844. With the cutoff of
0.2, a sensitivity of 86.7 and specificity of 75.5 % were re-
ported [11]. LRM has shown promising results for prog-
nosis prediction in HBV-ACLF ever since its introduction
into clinical application. Yang et al. compared the predict-
ive performance of MELD with that of LRM in a popula-
tion of 273 HBV-ACLF patients. In ACLF patients with
liver cirrhosis (LC), the AUC of LRM (0.851) was compar-
able with that of MELD (0.840). Yet, in patients with non-
cirrhotic ACLF, the AUC of LRM (0.897) was significantly
higher than that of MELD (0.758) [12].
In a previous study, we reported that ALSS could im-
prove short- and long-term prognosis in patients with
HBV-ACLF [13]. Here we reanalyzed the data in order
to determine whether better decisions for ALSS treat-
ment could be made with a model (e.g. MELD or LRM)
than without, through decision curve analysis.
Methods
Study patients
From January 2003 to December 2007, all patients admit-
ted to our hospital with the diagnosis of HBV-ACLF ac-
cording to the Chinese guidelines [14, 15] were screened.
Eligible patients were enrolled with the following criteria:
(i) aged between 18 and 70 years; (ii) presumptively diag-
nosed as hepatitis B surface antigen (HBsAg) carrier,
chronic hepatitis B (CHB) or HBV-related liver cirrhosis
(HBC); (iii) progressive hyperbilirubinemia, with serum
total bilirubin (TBil) ≥10 mg/dL; (iv) coagulopathy with
plasma prothrombin activity (PTA) ≤40 % or international
normalized ratio (INR) >1.5; (v) within 4 weeks from
symptom onset complicated by ascites and/or HE. ACLF is
further classified into early stage (30 % < PTA ≤ 40 %) and
middle-to-end stage (PTA ≤ 30 %) [15]. Some patients were
excluded according to the following criteria: acute HBV in-
fection, super-infection with other viruses, chronic liver
failure, coexistence of hepatocellular carcinoma (HCC), se-
vere gastrointestinal bleeding, pregnancy, or liver trans-
plant recipients.
The primary endpoint was 3-month survival. The second-
ary endpoint was survival at 5 years after diagnosis of ACLF.
The medical profiles of the patients were retrospect-
ively analyzed in the present study. Our study protocol
was approved by the institutional review board (IRB) of
Nantong Third People’s Hospital, Nantong University
and conducted in accord with the ethical guidelines of
the Declaration of Helsinki 1975. Patient consents were
waived by the same IRB.
MELD calculation
MELD score (range from 6 to 40) was calculated accord-
ing to the standard formula [16]. MELD = 11.2 × ln(INR)
+ 9.6 × ln[creatinine (mg/dL)] + 3.8 × ln[TBil (mg/dL)] +
6.4 (constant for liver disease etiology). Laboratory
values of bilirubin, INR or creatinine less than 1 were
rounded off to 1, in order to avoid negative scores. Cre-
atinine greater than 4 mg/dL or with renal replacement
therapy was capped at 4 mg/dL. In addition, the factor
for etiology of liver disease was not used.
LRM calculation
LRM score was calculated in accordance with the original
reference [11]. LRM=−1.343 + 0.772 ×HE + 2.279 ×HRS
+ 0.85 × LC + 1.026 ×HBeAg − 2.117 × PTA/age. For HE,
hepatorenal syndrome (HRS), LC and hepatitis B e antigen
(HBeAg), yes/positive = 1 while no/negative = 0. The score
was rounded to the nearest tenth.
ALSS treatment
The patients with HBV-ACLF were assigned randomly to
groups either given ALSS combined with standard medical
therapy (SMT) or only SMT. The randomization was con-
ducted by the Department of Epidemiology and Medical
Statistics, Nantong University based on the SAS module,
as we described in a previous study [13].
Statistical analysis
The accuracy of PTA, MELD or LRM was evaluated sep-
arately. For each model, the AUC, sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV), as well as diagnostic odds ratio (DOR), with the
95 % confidence intervals (CIs) were evaluated.
A simple decision tree is constructed with the HBV-
ACLF patients in Fig. 1. The splitting parameter is recom-
mendation for ALSS treatment or not. The a, b, c and d
showing live or dead cases in each group, give the values
of true positive, false positive, false negative, and true
negative respectively. A cost-effective analysis, proposed
by Vickers [17–19], was performed for each model using
decision curve analysis (DCA). The net benefit of a model
was estimated by the difference between the number of
true-positive and false-positive, weighted by the odds of
the specific threshold probability (Pt). A threshold value
of, for example, 20 % indicates that survival probability of
a treated patient is 80:20 = 4 times higher than the compli-
cations of an unnecessarily treated patient. Furthermore,
using LRM for a particular patient, Pt of 10 % indicates
that his possibility of LRM< 0.2 (ALSS treatment recom-
mended) is 90:10 = 9 times higher than that of LRM ≥ 0.2
(ALSS treatment unnecessary). The net benefit of a model
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compared with another model or with the reference net
benefit could be interpreted as the net increase in the pro-
portion of cases identified. We calculate net benefit using
the following formula [17]: net benefit = a/N – b/N × [Pt/(1-
Pt)]. We set a zero net benefit by assuming no patient
undergoing ALSS; on the contrary, we calculated the refer-
ence by assuming that all patients had undergone ALSS
treatment. For any given threshold probability (Pt) cut point,
the preferred model would be that with greater net benefit.
The reduction in the number of unnecessary ALSS is calcu-
lated using the following formula [17]: reduction of avoidable
ALSS treatment per 100 patients = (net benefit of the model
– net benefit of treat all)/[Pt/(1 – Pt)] × 100. The value is net
of false negatives and is hence the equivalent to the reduc-
tion number of unnecessary ALSS without a decrease in the
number of patients with ACLF who duly need ALSS.
All statistical analysis, including the DCA and plots im-
plementation, were done using Stata version 13 (StataCorp,
TX, USA). DCA analysis was performed using the code
found at https://www.mskcc.org/departments/epidemiolo-
gybiostatistics/health-outcomes/decision-curve-analysis-01
according to its tutorials.
Results
Patient characteristics
A total of 283 patients diagnosed with HBV-ACLF were
screened for inclusion in this study cohort. Among these,
51 patients were excluded from this study: five for age over
70 years, eight for super-infection with hepatitis E virus,
two for coexistence of HCC, seven for liver transplantation,
29 for incomplete data. Thus the final cohort compromised
232 patients with complete medical records.
The study cohort had a median (range) age of 45 (21–69)
years, with 77 % male (Table 1). Cirrhosis was preexisted in
112 (48.3 %) patients. The mean HBV DNA was 4.1 ± 2.5 lg
copies/ml and 142 patients (61.2 %) were hepatitis B e anti-
gen (HBeAg) positive. Moreover, the mean (SD) value of
serum bilirubin was 22.2 (9.2) mg/dL, PTA 27.1 % (16.8 %),
INR 4.2 (2.2), serum creatinine 0.93 (0.74) mg/dL, and albu-
min 32.1 (5.0) g/L. The most common complications were
ascites (194 patients; 83.6 %), spontaneous bacterial periton-
itis (SBP, 152 patients, 65.5 %), HE (64 patients; 27.67 %),
and HRS (37 patients; 16 %). Of these, 104 (44.8 %) patients
received ALSS therapy. 121 (52.2 %) patients survived the
first 3 months of follow-up (Table 1, Fig. 2).
Predictive performance of the models
As recommended by previous studies, the cutoffs for PTA,
MELD and LRM models were set for 30 %, 30 and 0.2 re-
spectively. With the cut-off value of 30 %, PTA had sensi-
tivity of 39.7 %, specificity of 77.5 %, PPV of 65.8 %, NPV of
54.4 %, AUC of 0.59 and DOR of 2.26. With the cut-off
value of 30, MELD had sensitivity of 55 %, specificity of
70.2 %, PPV of 62.9 %, NPV of 63 %, AUC of 0.63 and
DOR of 2.88. With the cut-off value of 0.2, LRM had sensi-
tivity of 92.6 %, specificity of 42.3 %, PPV of 63.6 %, NPV of
83.9 %, AUC of 0.68 and DOR of 9.14. LRM showed super-
ior discrimination over the others (Table 2).
Fig. 1 A decision tree of ALSS treatment for HBV-ACLF patients. The
a, b, c, and d give, respectively, the value of true positive, false
positive, false negative, and true negative
Table 1 Demographic, clinical and laboratory features of the
study patients
Characteristic Value
Number of patients 232
Male/female 178 (76.7 %)/54
(23.3 %)
Age (years) 46.1 ± 10.5
(45; 21–69)
HBeAg positivity 142 (61.2 %)
HBV DNA (lg copies/mL) 4.1 ± 2.5
TBil (mg/dL) 22.2 ± 9.2
Cr (mg/dL) 0.93 ± 0.74
PTA (%) 27.1 ± 16.8
INR 4.2 ± 2.2
Albumin (g/L) 32.1 ± 5.0
Preexisting cirrhosis 112 (48.3 %)
Ascites 194 (83.6 %)
SBP 152 (65.5 %)
HE 64 (27.6 %)
HRS 37 (16.0 %)
MELD 29.0 ± 5.4
LRM −0.6 ± 1.4
ALSS treatment 104 (44.8 %)
3-month survival 121(52.2 %)
Note: Data presented as mean ± standard deviation or n (%)
TBil total bilirubin, PTA prothrombin activity, INR international normalized ratio,
SBP spontaneous bacterial peritonitis, HE hepatic encephalopathy, HRS
hepatorenal, syndrome, MELD model for end-stage liver disease, LRM logistic
regression model, ALSS artificial liver support system
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Decision curve analysis
In Table 3, where LRM model was applied, the total num-
ber of patients (N) is 232, the true-positive count is 112,
and the false-positive count is 64. The net benefit for LRM-
guided treatment is therefore (112/232) – (64/232) × [Pt/(1-
Pt)]. The true- and false-positive counts for the “treat all”
strategy simply are the number of patients with and with-
out ALSS treatment respectively [17]. Calculating net bene-
fit for “treat all” gives (121/232) – (111/232) × [Pt/(1-Pt)]
while removing LRM model in all patients.
Decision curves for ACLF treatment, with the 3 ana-
lyzed models, were plotted in Fig. 3 to estimate the results
in a clinical context. The net benefit of the single marker
PTA was similar to the net benefit of random ALSS as-
signment. LRM-guided ALSS compared with “treating all”
strategy lead to a greater net benefit for ever probability
threshold starting from 16 %. Besides, it was always higher
than the net benefit of MELD-guided strategy. Both the
LRM and MELD model showed a superior net benefit
compared with the random ALSS assignment. The net
benefit of 0 at a Pt of 16 % could be interpreted in terms
that if we perform ALSS based on LRM score, the conse-
quence is equivalent to ALSS for all patients. Furthermore,
at a Pt of 64 %, the net benefit for the prediction model is
0.321 greater than assuming all patients need ALSS. The
net benefit formula was used to calculate which was the
equivalent of a net 0.321 × 100/(0.64/0.36) = 18 fewer false
positive results per 100 patients. It means that use of the
prediction model might result in the equivalent of 18 %
fewer ALSS in patients with ACLF, with no increase in the
number of patients who need ALSS left untreated. For
higher Pt (>64 %), the option to “not treat” is preferred
and neither predictive model has value (Fig. 3, Table 4).
Discussion
Artificial liver support system was first applied to treat
acute liver failure in 1970s with the attempt to replace
certain detoxification function of the liver. On the one
hand, the therapy cost is as expensive as nearly
$US2500 for each session of ALSS in China. The inci-
dence of adverse events (i.e. bleeding, hypotension, in-
fection, coagulopathy, and catheter-related events) were
reported [5, 6, 8, 13, 20]. On the other hand, several
clinical trials and systemic reviews suggested that ALSS
Fig. 2 Cumulative survival in HBV-ACLF patients over follow-up of 90 days
Table 2 Performance the models to predict 3-month outcome
with the recommended cutoffs
Model PTA MELD LRM
cutoff 30 % 30 0.2
Sensitivity 39.7 % 55 % 92.6 %
Specificity 77.5 % 70.2 % 42.3 %
PPV 65.8 % 62.9 % 63.6 %
NPV 51.4 % 63 % 83.9 %
AUC 0.59 (0.53–0.64) 0.63 (0.56–0.69) 0.68 (0.62–0.73)
DOR 2.26 (1.28–4.01) 2.88 (1.68–4.93) 9.14 (4.25–19.6)
PTA prothrombin activity, MELD model for end-stage liver disease, LRM logistic,
regression model, PPV positive predictive value, NPV negative predictive value,
AUC area under the receiving operating characteristic curve, DOR diagnostic
odds ratio
Table 3 Relationship between True ALSS Treatment and Result
of a LRM-guided ALSS Treatment
ALSS
N = 232 Live Dead
LRM model: Yes 112 64
LRM < 0.2 No 9 47
Note: net benefit of LRM model = 112/232 – 64/232× [Pt/(1-Pt)], net benefit of
treat all = 121/232 – (111/233) × [Pt/(1-Pt)]
ALSS artificial liver support system, LRM logistic regression model, Pt
threshold probability
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could reduce mortality in ACLF patients compared with
standard medical therapy [21–24]. Therefore, ALSS has
been recommended as one important method for the
treatment of ACLF [1, 15, 25, 26].
It has been extensively debated whether to treat all
ACLF patients or to treat selected patients. Some efforts
have been made toward the identification of factors or
models for predicting the prognosis after ALSS. For in-
stance, many factors, including HE, PTA, bilirubin, cre-
atinine, sodium, preexisting cirrhosis and age, were
found as independent predictors for the short-term sur-
vival rate in ACLF [13]. Several models such as MELD
and LRM, with recommended cutoff values, have been
proposed to predict the survival outcomes of ACLF pa-
tients [11, 27]. Since their introduction into clinical
practice, the MELD and LRM scores have been tested in
quite a few studies. Yet wide range of sensitivity and spe-
cificity has been reported in predicting mortality of
ACLF patients [9, 10, 12, 28]. Despite the well-known
utility of MELD in allocating donor livers [27], the clin-
ical utility of MELD and other models for other treat-
ments remains unclear.
Although discrimination and calibration are essential
aspects of a prediction model, they do not evaluate clin-
ical usefulness such as the ability to make better deci-
sions with a model than without. Decision curve analysis
is a method for assessing the benefits of a model
through a range of patient preferences in accepting risk
of overtreatment and undertreatment to facilitate deci-
sion making [29, 30]. The hypothesis in our study was
that we may make better decisions for ALSS treatment
with a model (e.g. MELD or LRM) than without. For a
prediction model aiming to guide therapeutic decisions,
a cut-off is required for the decision threshold. Right at
the threshold, the likelihood of benefit, e.g. improved
survival as a result of ALSS treatment, exactly balances
the likelihood of harm, e.g. adverse events and expensive
costs. However, as empirical evidence for the relative
weight of benefits and harms is often lacking, it is always
not easy to define a threshold.
In this study, we applied the DCA to evaluate the
cost/benefit ratio of one single marker (i.e. PTA) and
two models (i.e. MELD and LRM). The utility of PTA
alone resulted in no more net benefit gain than random
ALSS assignment. Using the MELD or LRM scores,
some number of unnecessary ALSS treatment could be
avoided at the cost that only a small proportion of pa-
tients with HBV-ACLF being advised not to undergo
ALSS treatment. Starting from the cutoff of 16 %, the
net benefit gain of LRM-guided strategy starts to be re-
markable. The DCA results showed that for patients
with threshold probabilities between 0 and 16 %, rela-
tively preferring for empirical therapy, the net benefit is
the greatest if all patients are treated. Across this range
of threshold probabilities, patients tend to be more con-
cerned about missing a timely treatment than about re-
ceiving unnecessary one. For the midrange threshold
probabilities between 16 and 64 %, the LRM-guided
ALSS therapy is superior to other strategies, including
the MELD score. For higher thresholds (>64 %) at which
patients appear be more concerned about unnecessary
Fig. 3 Decision curve for prediction of net benefit in ALSS treatment
for HBV-ACLF patients. Red line: assume no patient was treated with
ALSS (“treat none”). Green dash line: assume all patients were treated
with ALSS (“treat all). Pink line: assume only patients with higher PTA
(>30 %) were treated with ALSS. Yellow line: patients were treated
with random ALSS assignment. Purple line: assume only patients with
low MELD scores (<30) were treated with ALSS. Blue line: assume
only patients with low LRM scores (<0.2) were treated with ALSS
Table 4 Net Benefit for ALSS for All ACLF Patients or According to LRM, Using a Threshold of Pt
Pt
(%)
Net Benefit Advantage of LRM-guided ALSS
ALSS for All LRM-guided ALSS Net Benefit Reduction in Avoidable
ALSS per 100 Patients
16 0.430 0.430 0 0
20 0.402 0.414 0.012 5
30 0.317 0.365 0.048 11
40 0.203 0.299 0.096 14
50 0.043 0.207 0.164 16
60 −0.197 0.069 0.266 18
64 −0.329 −0.008 0.321 18
Note: The reduction in the number of unnecessary ALSS per 100 patients is calculated as follows: (net benefit of the model – net benefit of treat all)/[Pt/(1 – Pt)] × 100
ALSS artificial liver support system, ACLF, acute-on-chronic liver failure, LRM logistic regression model, Pt threshold probability of risk
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treatment than missed one, the option to not treat is
preferred and none of the predictive models has value.
Admittedly, there are some limitations in our study. First,
we applied the decision curve analysis theory retrospect-
ively with our cohort. Second, our findings were based on a
small sample size. Finally, the present methodology may be
appropriate for point decision making but not necessarily
for decisions which reoccur over time, because the scores
may frequently change in the natural history of ACLF.
Conclusions
Our findings indicate that the use of LRM-guided ALSS
treatment could increase both the accuracy and efficiency
of this procedure. Promising results from studies on the
novel LRM score for ACLF prognosis may lead to better
accuracy when predicting post-treatment outcomes in the
near future, allowing the avoidance of unnecessary ALSS.
Abbreviations
ACLF, acute-on-chronic liver failure; ALSS, artificial liver support system; AUC,
area under the receiving operating characteristic curve; CHB, chronic
hepatitis B; CI, confidence interval; DCA, decision curve analysis; DOR,
diagnostic odds ratio; HBC, HBV-related cirrhosis; HBeAg, hepatitis B e
antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC,
hepatocellular carcinoma; HE, hepatic encephalopathy; HRS, hepatorenal
syndrome; INR, international normalized ratio; IRB, institutional review
board; LC, liver cirrhosis; LRM, logistic regression model; MELD, model for
end-stage liver disease; NPV, negative predictive value; PPV, positive
predictive value; Pt, threshold probability; PTA, prothrombin activity; SBP,
spontaneous bacterial peritonitis; SMT, standard medical therapy; TBil,
total bilirubin
Acknowledgements
We would like to thank Prof. Lu-Jun Wang from Nantong Third People’s Hospital,
Nantong University for patient health record, Mr Xu-Lin Wang and Mr Sheng
Zhang from School of Public Health, Nantong University for data acquisition.
Funding
This study was supported in part by grant number 81370520 from National
Natural Science Foundation of China (NSFC), by the Grant for Clinical
Research number BE2015655 from the Department of Science and
Technology, Jiangsu Province, China, by grant number BK2012653 from the
Natural Science Foundation of Jiangsu Province, China, by the Young
Investigator Grant number Q201208 from the Department of Health, Jiangsu
Province, China, and by grant number MS12015004 from the Nantong
Science and Technology Bureau, Jiangsu Province, China. The funding
agreement ensured the authors’ independence in designing the study,
interpreting the data, writing, and publishing the report.
Availability of data and materials
Our dataset consists of patient data provided by Nantong Third People’s
Hospital, Nantong University can only be shared with its written consent.
Authors’ contributions
GQ conceived the research idea and study design and prepared the
manuscript. Z-LB carried out the field study and did data analysis. YS did data
analysis. LZ provided valuable discussion and support. X-HZ carried out the
field study and interpreted the results. Y-ML carried out the field study and
performed the statistical analysis. J-GS participated in the study design and
coordination and helped to refine the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Center for Liver Diseases, Nantong Third People’s Hospital, Nantong
University, Jiangsu, China. 2Department of Epidemiology and Medical
Statistics, School of Public Health, Nantong University, Jiangsu, China.
3Faculty of Medicine, Nursing and Health Science, Monash University,
Melbourne, VIC, Australia.
Received: 14 November 2015 Accepted: 29 May 2016
References
1. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC. Acute-
on-chronic liver failure: consensus recommendations of the Asian Pacific
Association for the study of the liver (APASL). Hepatol Int. 2014;8:453–71.
2. Li LJ, Zhang YM, Liu XL, Du WB, Huang JR, Yang Q, Xu XW, Chen YM.
Artificial liver support system in China: a review over the last 30 years. Ther
Apher Dial. 2006;10(2):160–7.
3. Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu
J. The efficacy and safety of nucleos(t)ide analogues in the treatment of
HBV-related acute-on-chronic liver failure: a meta-analysis. Ann Hepatol.
2013;12(3):364–72.
4. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED,
Lauchart W, Peszynski P, Freytag J, et al. Improvement of hepatorenal
syndrome with extracorporeal albumin dialysis MARS: results of a prospective,
randomized, controlled clinical trial. Liver Transpl. 2000;6(3):277–86.
5. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S,
Loehr M, Liebe S, Mitzner S, et al. Albumin dialysis in cirrhosis with
superimposed acute liver injury: a prospective, controlled study. Hepatology.
2002;36(4 Pt 1):949–58.
6. Hassanein TI, Tofteng F, Brown Jr RS, McGuire B, Lynch P, Mehta R, Larsen
FS, Gornbein J, Stange J, Blei AT. Randomized controlled study of
extracorporeal albumin dialysis for hepatic encephalopathy in advanced
cirrhosis. Hepatology. 2007;46(6):1853–62.
7. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, Sarrazin
C, Hoste E, Van Vlierberghe H, Escorsell A, et al. Effects of fractionated
plasma separation and adsorption on survival in patients with acute-on-
chronic liver failure. Gastroenterology. 2012;142(4):782–789.e783.
8. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba F,
Sauerbruch T, Klammt S, Ockenga J, et al. Extracorporeal albumin dialysis
with the molecular adsorbent recirculating system in acute-on-chronic liver
failure: the RELIEF trial. Hepatology. 2013;57(3):1153–62.
9. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in
lamivudine treatment for patients with acute-on-chronic hepatitis B liver
failure. J Gastroenterol Hepatol. 2010;25(3):583–90.
10. Xia Q, Dai X, Huang J, Xu X, Yang Q, Liu X, Chen Y, Li L. A single-center
experience of non-bioartificial liver support systems among Chinese
patients with liver failure. Int J Artif Organs. 2014;37(6):442–54.
11. Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to
determine 3-month mortality risk in patients with acute-on-chronic hepatitis
B liver failure. Clin Gastroenterol Hepatol. 2011;9(4):351–6. e353.
12. Yang WB, Chen EQ, Bi HX, Bai L, Chen XB, Feng P, Tang H. Different models
in predicting the short-term prognosis of patients with hepatitis B virus-
related acute-on-chronic liver failure. Ann Hepatol. 2012;11(3):311–9.
13. Qin G, Shao JG, Wang B, Shen Y, Zheng J, Liu XJ, Zhang YY, Liu YM, Qin Y,
Wang LJ. Artificial liver support system improves short- and long-term
outcomes of patients with HBV-associated acute-on-chronic liver failure:
a single-center experience. Medicine. 2014;93(28):e338.
14. Si CW, Zhuang H. Prevention and cure project of viral hepatitis. Zhonghua
Gan Zang Bing Za Zhi. 2000;8(6):324–9.
15. Li LJ. Diagnostic and treatment guidelines for Iiver failure. Zhonghua Gan
Zang Bing Za Zhi. 2006;14(9):643–6.
16. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT,
Edwards E, Therneau TM. Hyponatremia and mortality among patients on
the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018–26.
17. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating
prediction models. Med Decis Mak. 2006;26(6):565–74.
18. Vickers AJ, Kattan MW, Daniel S. Method for evaluating prediction models that
apply the results of randomized trials to individual patients. Trials. 2007;8:14.
19. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve
analysis, a novel method for evaluating diagnostic tests, prediction models
and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.
Qin et al. BMC Medical Informatics and Decision Making  (2016) 16:59 Page 6 of 7
20. Wigg AJ, McCormick R, Wundke R, Woodman RJ. Efficacy of a chronic
disease management model for patients with chronic liver failure. Clin
Gastroenterol Hepatol. 2013;11(7):850–8. e851-854.
21. Liu JP, Gluud LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support
systems for liver failure. Cochrane Database Syst Rev. 2004;1:CD003628.
22. Shen Y, Wang XL, Wang B, Shao JG, Liu YM, Qin Y, Wang LJ, Qin G. Survival
benefits with artificial liver support system for acute-on-chronic liver failure:
a time series-based meta-analysis. Medicine. 2016;95(3):e2506.
23. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support
systems for acute and acute-on-chronic liver failure: a systematic review.
JAMA. 2003;289(2):217–22.
24. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, Stauber RE.
Effect of extracorporeal liver support by MARS and prometheus on serum
cytokines in acute-on-chronic liver failure. Crit Care. 2006;10(6):R169.
25. Li LJ. Diagnostic and treatment guidelines for Iiver failure. Zhonghua Gan
Zang Bing Za Zhi. 2012;21(3):177–83.
26. Hessel FP, Bramlage P, Wasem J, Mitzner SR. Cost-effectiveness of the
artificial liver support system MARS in patients with acute-on-chronic liver
failure. Eur J Gastroenterol Hepatol. 2010;22(2):213–20.
27. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W,
Lake J, Howard T, Merion RM, et al. Model for end-stage liver disease
(MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.
28. Shen Y, Liu YM, Wang B, Zhu YG, Wang YY, Wang XL, Ji JL, Shao JG, Qin Y,
Qin G. External validation and comparison of six prognostic models in a
prospective cohort of HBV-ACLF in China. Ann Hepatol. 2016;15(2):236–45.
29. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models:
seven steps for development and an ABCD for validation. Eur Heart J. 2014;
35(29):1925–31.
30. Fitzgerald M, Saville BR, Lewis RJ. Decision curve analysis. JAMA. 2015;313(4):
409–10.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Qin et al. BMC Medical Informatics and Decision Making  (2016) 16:59 Page 7 of 7
